1401449-61-3

Upstream product

• 1360899-50-8 6-bromo-1H-1,3-benzodiazol-4-amine 
• 1365243-78-2 [4-(cyclopropylcarbamoyl)-3-methylphenyl]boronic acid 
• 1121586-23-9 5-bromobenzene-1,2,3-triamine 
• 1351374-48-5 N-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 62554-90-9 4-bromo-2,6-dinitroaniline 
• 345965-99-3 4-bromo-N-cyclopropyl-2-methylbenzamide 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 606-22-4 2,6-dinitroaniline 

Downstream Products

• 1401449-62-4 4-{6-bromo-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide 
• 1401449-67-9 N-cyclopropyl-4-{6-[(5-fluoro-2-methylphenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide 
• 1401449-66-8 N-cyclopropyl-2-methyl-4-{6-(pyridin-4-yl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLES

The present invention relates to substituted benzimidazole compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.